Get the Stockscreener App
0.4491
5.52%
0.0235
After Hours:
.45
0.0009
+0.20%
Applied Therapeutics Inc stock is traded at $0.4491, with a volume of 600.88K.
It is up +5.52% in the last 24 hours and up +8.50% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.4256
Open:
$0.43
24h Volume:
600.88K
Relative Volume:
0.30
Market Cap:
$63.58M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.3327
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-4.45%
1M Performance:
+8.50%
6M Performance:
-22.07%
1Y Performance:
-92.77%
1-Day Range:
$0.43
$0.4587
1-Week Range:
$0.422
$0.4833
52-Week Range:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.4491 | 60.25M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Applied Therapeutics Inc.’s Beta Climbs After Market VolatilityBuy Alerts With Low Risk Confirmation Noted - metal.it
Applied Therapeutics (APLT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
What institutional investors are buying Applied Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What are the latest earnings results for Applied Therapeutics Inc.Free Stock Selection - Jammu Links News
What are analysts’ price targets for Applied Therapeutics Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
What catalysts could drive Applied Therapeutics Inc. stock higher in 2025Achieve breakthrough financial results - Jammu Links News
How does Applied Therapeutics Inc. generate profit in a changing economyInvest confidently with professional market insights - Jammu Links News
What are Applied Therapeutics Inc. company’s key revenue driversHigh-octane investment opportunities await - Jammu Links News
How volatile is Applied Therapeutics Inc. stock compared to the marketGet high-impact stock recommendations now - Jammu Links News
Published on: 2025-08-03 15:52:53 - Jammu Links News
Applied Therapeutics Inc. Stock Analysis and ForecastBuild a diversified portfolio for risk management - Jammu Links News
What drives Applied Therapeutics Inc. stock priceMaximize your portfolio’s growth potential - Jammu Links News
What analysts say about Applied Therapeutics Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
What makes Applied Therapeutics Inc. stock price move sharplyEarnings Report Entry Points For Fast Growth - Jammu Links News
Applied Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Brokerages Set Applied Therapeutics Inc. (NASDAQ:APLT) PT at $6.10 - MarketBeat
What is the dividend policy of Applied Therapeutics Inc. stockValue Investing Picks For Every Investor - Jammu Links News
Is Applied Therapeutics Inc. still worth holding after the dipBuy Alerts With Low Risk Confirmation Noted - metal.it
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit – APLT - ACCESS Newswire
Wall Street Zen Upgrades Applied Therapeutics (NASDAQ:APLT) to Sell - MarketBeat
Published on: 2025-07-29 13:58:52 - metal.it
Why Applied Therapeutics Inc. stock attracts strong analyst attentionLow Capital High Return Stock Plans Reviewed - metal.it
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
How does Applied Therapeutics Inc. compare to its industry peersRemarkable growth - jammulinksnews.com
Applied Therapeutics (NASDAQ:APLT) Stock Price Down 5%What's Next? - MarketBeat
What is Applied Therapeutics Inc. company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
Published on: 2025-07-28 02:44:29 - Jammu Links News
Is Applied Therapeutics Inc. a good long term investmentFree Consultation - PrintWeekIndia
Should I buy Applied Therapeutics Inc. stock before earningsFree Investment Risk Control - Jammu Links News
How Applied Therapeutics Inc. stock reacts to Fed policy changesTop Analyst Picks - Newser
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):